Correction to: Trials (2020) 21:1005
https://doi.org/10.1186/s13063-020-04878-y
Following publication of the original article [1], we were notified that the figure of the study design in the paper was an older, incorrect figure that did not correctly reflect randomization strategy, patient numbers, and intervention. The incorrect and correct figures are presented below.
-
Originally published figure
-
Corrected figure
The original article has been corrected.
Reference
Vanassche T, et al. A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials. 2020;21:1005. https://doi.org/10.1186/s13063-020-04878-y.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Vanassche, T., Engelen, M.M., Van Thillo, Q. et al. Correction to: A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study. Trials 21, 1033 (2020). https://doi.org/10.1186/s13063-020-04991-y
Published:
DOI: https://doi.org/10.1186/s13063-020-04991-y